Agreements

Date: 2016-05-10

Type of information: Research agreement

Compound: monoclonal antibodies against multiple targets

Company: Achaogen (USA - CA) Crystal Bioscience (USA - CA)

Therapeutic area: Infectious diseases

Type agreement: R&D - research - licensing

Action mechanism: monoclonal antibody. Crystal Bioscience has developed a therapeutic antibody discovery engine using chickens. Its platform is "powered by evolution," exploiting the large phylogenetic distance between mammals and birds to generate a diverse array of antibodies to human targets that have proven intractable in mammalian and other discovery platforms.

Disease:

Details:

• • On May 10, 2016, Achaogen and Crystal Bioscience announced that they have entered into a multiyear collaboration and license agreement to discover unique monoclonal antibodies against multiple targets. Achaogen has research and early development programs that are currently focused on discovering and developing novel medicines for serious infections caused by MDR gram-negative bacterial pathogens, including antibacterial monoclonal antibodies.
• Achaogen and Crystal Bioscience will collaborate on the discovery of monoclonal antibodies against multiple targets of therapeutic interest to Achaogen. Crystal Bioscience will conduct the initial discovery work with its chicken antibody platform, including its genetically-engineered chicken producing human antibodies and its proprietary high-throughput single B cell interrogation system (the patented Gel Encapsulated Microenvironment (GEM) assay).

Financial terms: Achaogen has agreed to provide applicable technology access fees, research funding, development milestones and royalty payments to Crystal Bioscience, and will have the right to develop and commercialize the antibodies discovered through this collaboration.

Latest news:

Is general: Yes